Paris, France and Manchester, UK – 19 May 2026 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces
ImmuPharma advances P140 partnering strategy following £6.5m raise
ImmuPharma PLC (AIM: IMM) said it is actively progressing partnering discussions for its lead autoimmune platform, P140, which remains its primary strategic focus for 2026.
ImmuPharma PLC advances P140 talks as new data strengthens programme
ImmuPharma PLC is stepping up efforts to secure a licensing deal for its P140 autoimmune platform, with discussions underway with multiple potential partners under confidentiality agreements.
genedrive plc (LON: GDR) New interactive investor hub
genedrive plc launches new interactive investor hub
genedrive plc (AIM: GDR) Scotland national roll-out of Genedrive® MT-RNR1 ID Kit
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to note the recent media coverage of its Genedrive® MT-RNR1 ID Kit, which reduces the risk of
genedrive plc (AIM: GDR) MT-RNR1 ID Kit in Dublin’s Rotunda Hospital
Genedrive® MT-RNR1 ID Kit implemented at Dublin’s Rotunda Hospital
Genedrive Shares Jump 22% on Talks Over £1 Million Shareholder Loan
Genedrive PLC (AIM: GDR) shares soared 22% to 1.04p after the diagnostics company confirmed it is in talks with major shareholder David Nugent regarding a potential £1 million loan to
ImmuPharma PLC (LON: IMM) Launch of New Website & Corporate Update
www.immupharma.co.uk
Tim McCarthy, Chief Executive Officer of ImmuPharma PLC talks to Zak Mir
Zak Mir talks to Tim McCarthy, CEO of Immupharma, the speciality biopharmaceutical company that discovers and develops peptide-based therapeutics, announcing the filing of a groundbreaking new patent application for its
genedrive plc (AIM: GDR) Comment re: Share Price Movement
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, notes the fall in the Company’s share price on 13 August 2025 which it believes was connected to postings
genedrive PLC (AIM: GDR) Expects Revenue to Double as Commercial Momentum Builds
Genedrive PLC (AIM: GDR), the developer of rapid genetic testing technology, expects total income for the year ended 30 June to rise to around £1 million, up from £0.5 million
Genedrive PLC (AIM:GDR) received European regulatory approval
Genedrive wins EU approval for rapid genetic test aimed at stroke and heart attack care